Medical Developments International (ASX:MVP) reported a 9% revenue increase to $42.6 million and a 566% jump in net profit to $0.6 million for FY26, driven by robust growth in its Pain Management segment and expanded paediatric approvals in Europe.
- 9% revenue growth to $42.6 million
- 566% net profit increase to $0.6 million
- 21% Pain Management revenue surge led by Penthrox
- 28% volume growth in Australian hospital segment
- Paediatric label approved and launched in Europe
Pain Management Drives Profit Rebound
Medical Developments International (ASX:MVP) has delivered a notable turnaround in FY26, lifting net profit after tax by 566% to $0.6 million, up from a modest $0.1 million the previous year. The company’s revenue climbed 9% to $42.6 million, with the Pain Management segment, anchored by its flagship inhaled analgesic Penthrox, posting a 21% revenue increase to $31.6 million. This growth was fuelled by higher volumes across all regions and improved pricing in Australia, where hospital segment volume jumped 28%.
The Respiratory segment, supplying devices for asthma and COPD, faced softer demand, leading to a 15% revenue decline to $10.9 million. However, pricing initiatives in the US and tariff refunds helped lift segment EBIT by 63% to $0.7 million despite the revenue drop.
European Paediatric Approval Expands Market
A key milestone was the approval and launch of a paediatric label for Penthrox in the UK and all European markets, extending the indication to children aged six and older. This regulatory win broadens the addressable market and underpins future growth prospects. In-market Penthrox volumes in Europe rose 18%, supported by stronger demand in the UK, Ireland, France, and Nordic countries, alongside increased inventory holdings by partners, partly due to the transition to a capital light partner distribution model in France and Switzerland.
The company also published the MAGPIE paediatric study and a health economic analysis demonstrating that Penthrox use in hospital emergency departments delivers whole-of-department cost and operational savings compared to standard care, strengthening its clinical and economic value proposition.
Cashflow Strengthens and Capital Discipline Maintained
Operating cash flow surged by $5.8 million to $5.8 million, reflecting improved earnings and a significant $5.2 million reduction in working capital usage, driven by lower inventory investment in the Respiratory segment and timing of receivables. Free cash flow rose to $4.2 million. The company ended FY26 with $21.4 million in cash and term deposits, maintaining a strong balance sheet and net cash position.
Capital expenditure was modest at $0.8 million, down from $1.0 million the previous year, with FY27 capex expected around $1.5 million, including amortisation of approximately $1 million related to the European paediatric registration costs.
Strategic Focus on Market Penetration and Margin Enhancement
Looking ahead to FY27, MVP plans to accelerate Penthrox penetration by leveraging the paediatric indication in Europe, expanding real-world evidence, and strengthening partner engagement. The company will also pursue growth in new markets and procedural segments, evaluate US market entry strategies, and seek operational efficiencies and margin enhancements through disciplined cost management and improved commercial terms.
Risks remain, notably supply chain disruptions in the Middle East and uncertainties around US tariffs, which the company continues to monitor. The business remains focused on executing its strategy to drive sustainable growth and shareholder value.
On governance, the company saw a leadership transition with Mark Fladrich appointed Chair in December 2025, bringing extensive pharmaceutical commercial experience. Executive remuneration outcomes reflected the company’s improved financial performance, with STI awards aligned to EBIT, free cash flow, and strategic milestones.
Medical Developments International’s FY26 results underscore the resilience and growth potential of its Pain Management franchise, particularly Penthrox, as it expands its clinical indications and geographic footprint. The challenge will be sustaining momentum amid softer Respiratory demand and navigating external risks in FY27.
Bottom Line?
MVP’s FY26 profit surge and Penthrox paediatric approval set the stage for growth, but execution risks and external uncertainties loom in FY27.
Questions in the middle?
- How will MVP sustain Pain Management growth beyond the paediatric label expansion?
- What strategies will MVP deploy to counteract softer demand in the Respiratory segment?
- How might ongoing Middle East supply chain issues and US tariffs impact FY27 earnings?